Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...
The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Alterity Therapeutics ATHE shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. T ...